The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis
Abstract
Fourteen patients with multiple sclerosis were treated with the humanized monoclonal antibody CAMPATH-1H which targets the CD52 antigen present on all lymphocytes and some monocytes; four also received anti-CD4 antibody. Lymphopaenia developed rapidly and was sustained for at least 1 year. In 12 patients, the first infusion of antibody was characterized by significant exacerbation or re- awakening of pre-existing symptoms lasting several hours. These clinical effects of antibody treatment correlated with increased levels of circulating cytokines. Peak levels of tumour necrosis factor (TNF)-alpha and interferon (IFN)-gamma occurred at 2 h, whereas the rise in interleukin-6 (IL-6) was significantly delayed and peaked at 4 h after starting antibody treatment. There was a decline in CH50, indicating complement activation. The neurological symptoms could not be attributed directly to pyrexia and were not provoked (in one patient) by an artificial rise in temperature. In the remaining two patients, a single pre-treatment with intravenous methylprednisolone (500 mg) prevented both the transient increase in neurological symptoms and the cytokine release. Our results, involving 14 intensively studied patients treated with humanized monoclonal antibodies, suggested that soluble immune mediators contribute to symptom production in multiple sclerosis; the mechanism remains uncertain but, on the available evidence, we favour the interpretation that cytokines directly affect conduction through partially demyelinated pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
Exacerbations of multiple sclerosis in patients treated with gamma interferon
Panitch, H., Haley, A., Hirsch, R., & Johnson, K. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92863-7 · Cited by 1,071 · cited 1×
“, 1989), and an increased relapse rate has been associated with the therapeutic use of IFN-y (Panitch et al., 1987).”
BackgroundMurine tumor necrosis factor alpha is transported from blood to brain in the mouse
Gutierrez, E. G., Banks, W. A., & Kastin, A. J. (1993) · Journal of Neuroimmunology · doi:10.1016/0165-5728(93)90027-v · Cited by 577
Cited by
Coles, A. J., Twyman, C. L., Arnold, D. L., Cohen, J. A., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61768-1 · Cited by 1,198
Self-citationAlemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802670 · Cited by 1,017
Demyelination: The Role of Reactive Oxygen and Nitrogen Species
Smith, K. J., Kapoor, R., & Felts, P. A. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00212.x · Cited by 600
The role of nitric oxide in multiple sclerosis
Smith, K. J., & Lassmann, H. (2002) · The Lancet Neurology · doi:10.1016/s1474-4422(02)00102-3 · Cited by 531
The experimental autoimmune encephalomyelitis (EAE) model of MS
(2014) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-52001-2.00008-x · Cited by 464
Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis
Coles, A. J., Wing, M., Smith, S., Coraddu, F., Greer, S., Taylor, C., Weetman, A., Hale, G., Chatterjee, V. K., Waldmann, H., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)02429-0 · Cited by 453
Self-citationInvestigation of MS normal-appearing brain using diffusion tensor MRI with clinical correlations
Ciccarelli, O., Werring, D. J., Wheeler–Kingshott, C. A. M., Barker, G. J., Parker, G. J. M., Thompson, A. J., & Miller, D. H. (2001) · Neurology · doi:10.1212/wnl.56.7.926 · Cited by 349
Rituximab therapy of patients with B-cell chronic lymphocytic leukemia
Huhn, D. (2001) · Blood · doi:10.1182/blood.v98.5.1326 · Cited by 347
Smith, K. J., & McDonald, W. I. (1999) · Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences · doi:10.1098/rstb.1999.0510 · Cited by 340
Werring, D. J. (2000) · Brain · doi:10.1093/brain/123.8.1667 · Cited by 326
Redford, E. (1997) · Brain · doi:10.1093/brain/120.12.2149 · Cited by 326
Psychoneuroimmunology and the cytokine action in the CNS: Implications for psychiatric disorders
Müller, N., & Ackenheil, M. (1998) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(97)00179-6 · Cited by 306
Multiple sclerosis: Side effects of interferon beta therapy and their management
Walther, E. U., & Hohlfeld, R. (1999) · Neurology · doi:10.1212/wnl.53.8.1622 · Cited by 304
Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis
Cox, A. L., Thompson, S. A. J., Jones, J. L., Robertson, V. H., Hale, G., Waldmann, H., Compston, D. A. S., & Coles, A. J. (2005) · European Journal of Immunology · doi:10.1002/eji.200535075 · Cited by 291
Self-citationByrd, J. C., Waselenko, J. K., Maneatis, T. J., Murphy, T., Ward, F. T., Monahan, B. P., Sipe, M. A., Donegan, S., & White, C. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.791 · Cited by 264
van Oosten, B. W., Lai, M., Hodgkinson, S., Barkhof, F., Miller, D. H., Moseley, I. F., Thompson, A. J., Rudge, P., McDougall, A., McLeod, J. G., et al. (1997) · Neurology · doi:10.1212/wnl.49.2.351 · Cited by 264
Hong, J., Li, N., Zhang, X., Zheng, B., & Zhang, J. Z. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502187102 · Cited by 264
Wing, M. G., Moreau, T., Greenwood, J., Smith, R. M., Hale, G., Isaacs, J., Waldmann, H., Lachmann, P. J., & Compston, A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119110 · Cited by 257
Self-citationAlemtuzumab treatment of multiple sclerosis: long-term safety and efficacy
Tuohy, O., Costelloe, L., Hill-Cawthorne, G., Bjornson, I., Harding, K., Robertson, N., May, K., Button, T., Azzopardi, L., Kousin-Ezewu, O., et al. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-307721 · Cited by 238
Self-citationImmune reconstitution syndrome and the thyroid
Weetman, A. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.07.003 · Cited by 87
After TGN1412: Recent developments in cytokine release assays
Stebbings, R., Eastwood, D., Poole, S., & Thorpe, R. (2013) · Journal of Immunotoxicology · doi:10.3109/1547691x.2012.711783 · Cited by 73
“Yet, when later compared with immobilized Campath-1H (an anti-CD52 mAb used for the treatment of B-cell chronic lymphocytic leukemia) and Rituximab, (an anti-CD20 mAb used to treat hematological neoplasm such as leukemia and lymphomas), two therapeutics known to induce cytokine release syndrome in some patients (Morea…”
BackgroundSeverity of the TGN 1412 trial disaster cytokine storm correlated with IL‐2 release
Eastwood, D., Bird, C., Dilger, P., Hockley, J., Findlay, L., Poole, S., Thorpe, S. J., Wadhwa, M., Thorpe, R., & Stebbings, R. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12165 · Cited by 58
Metadata
- Authors
- Moreau, T., Coles, A., Wing, M., Isaacs, J., Hale, G., Waldmann, H., & Compston, A.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 1996
- Volume
- 119
- Issue
- 1
- Pages
- 225-237
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2151735361
- Cited by
- 250
- References
- 3
- FWCI
- 11.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.